Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting
Oh W, Miao R, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M, Dhawan R, Duh M. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Medical Oncology 2017, 34: 160. PMID: 28795333, PMCID: PMC5550521, DOI: 10.1007/s12032-017-1014-2.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerProstate-specific antigenSecond-line therapy initiationCastration-resistant prostate cancerOverall survivalTherapy initiationProstate cancerPost-docetaxel metastatic castration-resistant prostate cancerMetastatic castration-resistant prostate cancer patientsPatient characteristicsAndrogen receptor-targeted therapiesFirst-line therapy initiationPost-docetaxel mCRPC patientsTreatment sequenceAssess treatment sequencingPost-docetaxel patientsReceptor-targeted therapyHigh-risk featuresNinety-five patientsHigh-risk patientsSecond-line ARTAlkaline phosphataseLower mean haemoglobinHigh-risk scoreMCRPC patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply